Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Spinraza

This page shows the latest Spinraza news and features for those working in and with pharma, biotech and healthcare.

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

Participants had been previously treated with other approved or investigational SMA-targeting therapies, including Spinraza (nusinersen) or Zolgensma (onasemnogene abeparvovec).

Latest news

More from news
Approximately 21 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Assessing the impact of rarity on French HTA and pricing decisions Assessing the impact of rarity on French HTA and pricing decisions

    Additional factors beyond eligible patient number. Looking at reimbursed products, Spinraza and Orkambi both sit above the trend and offer valuable insights into factors beyond eligible patient numbers. ... Spinraza is indicated for the treatment of 5q

  • #OrkambiNow? #OrkambiNow?

    But Orkambi is not the only orphan disease drug stuck in market access limbo in the England – Biogen’s Spinraza and BioMarin’s Kuvan are both currently suffering similar fates, and

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    only other SMA treatment available, Biogen’s Spinraza. ... The company argues that current ten- year costs of caring for SMA type 1 patients with Spinraza and additional care costs are somewhere between $2.5-$5m.

  • No incentive for a cure No incentive for a cure

    And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to  the health of motor ... And the lack of affordability - as well as the bad

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Article: Market access in Brazil

    All eyes on Spinraza. Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil? ... In April 2019, Brazilian Health Minister Luiz Henrique

  • Research Partnership Research Partnership

    Healthcare under AMLO – One year on. All eyes on Spinraza.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Quick links